| 1 |
NCT03657420 |
Not yet recruiting |
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma |
|
- Drug: ABI-009
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Aadi, LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose.
- Overall response rate.
- Progression free survival.
- Treatment-emergent adverse events.
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT03657420 |
18-252 |
|
September 30, 2018 |
September 30, 2021 |
September 30, 2024 |
September 5, 2018 |
September 5, 2018 |
|
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
|
|
| 2 |
NCT03336073 |
Recruiting |
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma |
|
- Drug: Carfilzomib
- Drug: Dexamethasone
- Drug: cyclophosphamide
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of carfilzomib, dexamethasone and cyclophosphamide in number of responses obtiened
- Safety of carfilzomib, dexamethasone and cyclophosphamide in Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
270 |
All |
18 Years and older (Adult, Older Adult) |
NCT03336073 |
GEM-KyCyDex |
|
December 18, 2017 |
December 2019 |
December 2021 |
November 8, 2017 |
February 8, 2019 |
|
- Hospital Universitario de Canarias
Tenerife, Islas Canarias, Spain - H.Universitari Germans Trias I Pujol de Badalona
Barcelona, Spain - Hospital Clinic i Provincial de Barcelona
Barcelona, Spain - (and 21 more...)
|
|
| 3 |
NCT03033316 |
Not yet recruiting |
A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma |
|
|
Interventional
|
Phase 1
Phase 2 |
- Enceladus Pharmaceuticals BV
- University Hospital, Aachen
- Accelovance
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Response according to IMWG Criteria
- Percentage change of myeloma-related measures
- (and 3 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT03033316 |
14-097 |
AMETHYST |
January 2017 |
December 2018 |
March 2019 |
January 26, 2017 |
January 26, 2017 |
|
|
|
| 4 |
NCT02692339 |
Recruiting |
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Adverse events of special interest during Len/Dex therapy
- Incidence (number) of thromboembolism
- Duration of Len/Dex treatment over the course of the study
- (and 2 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT02692339 |
CC-5013-MM-028 |
PrObe-L |
February 25, 2016 |
September 29, 2023 |
September 29, 2023 |
February 26, 2016 |
March 6, 2018 |
|
- Hospital Garcia Orta, E.P.E.
Almada, Portugal - Hospital Professor Doutor Fernando Fonseca, E.P.E.
Amadora, Portugal - Hospital Central de Faro
Faro, Portugal - (and 9 more...)
|
|
| 5 |
NCT02002598 |
Recruiting |
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma |
|
- Drug: Bendamustine
- Drug: Carfilzomib
- Drug: Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Siyang Leng
- Columbia University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Carfilzomib in combination with bendamustine and dexamethasone
- Overall response rate (ORR)
- Duration of response (DOR)
- (and 5 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT02002598 |
AAAJ2359 |
|
November 2013 |
May 30, 2019 |
July 30, 2019 |
December 6, 2013 |
January 31, 2019 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 6 |
NCT02963493 |
Recruiting |
A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients |
|
- Drug: Melflufen
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Oncopeptides AB
- Precision Oncology
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Duration of Response
- (and 3 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02963493 |
OP-106 |
HORIZON |
December 2016 |
March 2020 |
November 2021 |
November 15, 2016 |
November 27, 2018 |
|
- Innovative Clinical Research Institute (ICRI)
Whittier, California, United States - University of Florida
Gainesville, Florida, United States - RUSH
Chicago, Illinois, United States - (and 15 more...)
|
|
| 7 |
NCT02967276 |
Recruiting |
Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma |
|
- Drug: Metformin XR
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University of Campinas, Brazil
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (RR)
- Time to progression (TTP) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)
- Duration of response (DOR) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)
- Event free survival (EFS) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT02967276 |
METDEXA-MM |
METDEXA-MM |
January 2017 |
February 2018 |
February 2020 |
November 18, 2016 |
May 2, 2017 |
|
- UOPECCAN - Hospital do Câncer de Cascavel
Cascavel, PR, Brazil - Hemocentro - Hospital de Clínicas - State University of Campinas (UNICAMP)
Campinas, SP, Brazil
|
|
| 8 |
NCT03374085 |
Recruiting |
A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
- Drug: CC-92480
- Drug: Dexamethasone
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events (AEs)
- Pharmacokinetics- AUC
- Pharmacokinetics- Cmax
- (and 9 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03374085 |
CC-92480-MM-001
U1111-1205-3650
2017-001236-19 |
|
February 6, 2018 |
January 1, 2020 |
March 1, 2020 |
December 15, 2017 |
August 24, 2018 |
|
- City of Hope Cancer Center
Duarte, California, United States - Colorado Blood Cancer Institute
Denver, Colorado, United States - Emory Clinic
Atlanta, Georgia, United States - (and 15 more...)
|
|
| 9 |
NCT03001804 |
Recruiting |
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients receiving full dose of dexamethasone after 6 months
- Number of patients with Deep Venous Thrombosis (VTE) prophylaxis
- Over all response rate (ORR)
- Adverse Events (AEs)
|
56 |
All |
18 Years and older (Adult, Older Adult) |
NCT03001804 |
CC-5013-MM-037 |
|
July 31, 2017 |
December 30, 2021 |
December 31, 2021 |
December 23, 2016 |
January 30, 2019 |
|
- Landeskrankenhaus Kirchdorf
Kirchdorf, Austria - Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria - Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria - (and 7 more...)
|
|
| 10 |
NCT03746652 |
Not yet recruiting |
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Daratumumab, Ixazomib, Dexamethasone
|
Interventional
|
Phase 2 |
- Hellenic Society of Hematology
- Janssen Pharmaceutica NV
- Takeda Pharmaceuticals Company Ltd.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Evaluation of the hematologic and non-hematologic toxicity profile of the combination.
- Duration of response (DOR)
- (and 6 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03746652 |
ΕΑΕ-2018/ΜΜ03 |
DARIA |
December 2018 |
December 2021 |
December 2021 |
November 20, 2018 |
November 22, 2018 |
|
- General Hospital of Athens "Alexandra"
Athens, Attica, Greece
|
|
| 11 |
NCT02899052 |
Recruiting |
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) |
|
- Drug: Carfilzomib
- Drug: Venetoclax
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- AbbVie
- Genentech, Inc.
- Onyx Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events
- Objective Response Rate (ORR) of VenKd in participants with RRMM as well as those with t(11;14)-positive RRMM.
- Very Good Partial Response (VGPR) or better response rate of VenKd in participants with relapsed or refractory MM (RRMM) as well as those with t(11;14)-positive RRMM
- (and 15 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02899052 |
M15-538 |
|
January 19, 2017 |
March 27, 2020 |
October 16, 2022 |
September 14, 2016 |
October 31, 2018 |
|
- University of Alabama /ID# 151405
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences /ID# 151399
Little Rock, Arkansas, United States - Emory University Hospital /ID# 161710
Atlanta, Georgia, United States - (and 9 more...)
|
|
| 12 |
NCT03492138 |
Recruiting |
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma |
|
- Drug: ONC201
- Drug: Ixazomib
- Drug: Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Ajai Chari
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose (RPTD)
- Disease control rate
- Progression free survival (PFS)
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT03492138 |
GCO 17-2680 |
|
March 26, 2018 |
March 15, 2023 |
March 15, 2023 |
April 10, 2018 |
April 10, 2018 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 13 |
NCT03110562 |
Recruiting |
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma |
|
- Drug: Selinexor
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Karyopharm Therapeutics Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare progression-free survival (PFS) based on the Independent Review Committee's (IRC's) disease outcome assessments in patients randomized to the SVd Arm versus the Vd Arm
|
364 |
All |
18 Years and older (Adult, Older Adult) |
NCT03110562 |
KCP-330-023 |
BOSTON |
May 24, 2017 |
June 2020 |
June 2020 |
April 12, 2017 |
November 2, 2018 |
|
- Boca Raton Clinical Research (BRCR) Medical Center
Plantation, Florida, United States - Emory University
Atlanta, Georgia, United States - Kaiser Permanente Hawaii
Honolulu, Hawaii, United States - (and 162 more...)
|
|
| 14 |
NCT03439293 |
Recruiting |
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) |
|
- Drug: Ixazomib
- Drug: Daratumumab
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Very Good Partial Response (VGPR) or Better
- Progression-free Survival (PFS)
- Time to Progression (TTP)
- (and 4 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03439293 |
C16047
U1111-1202-6022
2017-003977-32 |
|
June 8, 2018 |
December 2, 2019 |
December 31, 2023 |
February 20, 2018 |
September 7, 2018 |
|
- Pacific Cancer Medical Center
Anaheim, California, United States - Colorado Blood Cancer Institute
Denver, Colorado, United States - SCRI - Florida Cancer Specialists - Panhandle
Tallahassee, Florida, United States - (and 25 more...)
|
|
| 15 |
NCT02199665 |
Recruiting |
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Refractory Multiple Myeloma
|
- Drug: selinexor
- Drug: carfilzomib
- Drug: dexamethasone
|
Interventional
|
Phase 1 |
- University of Chicago
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of selinexor, carfilzomib, and dexamethasone
- Incidence of toxicities related to the combination of selinexor and carfilzomib assessed using NCI CTCAE version 4.0
- Efficacy as measured by stable disease or better (including MR, partial response, very good partial response, complete response and stringent complete response) according to IMWG criteria
- Incidence of toxicities assessed using NCI CTCAE version 4.0
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02199665 |
IRB14-0033
NCI-2014-01199
P30CA014599 |
SINE |
June 12, 2014 |
April 2019 |
April 2019 |
July 24, 2014 |
April 11, 2018 |
|
- Mayo Clinic (AZ)
Scottsdale, Arizona, United States - University of Chicago
Chicago, Illinois, United States - University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States - (and 2 more...)
|
|
| 16 |
NCT03757221 |
Not yet recruiting |
Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma |
|
- Combination Product: Ixazomib and Daratumumab
|
Interventional
|
Phase 2 |
- University Hospital, Caen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Very Good Partial Response (VGPR) + Complete Response (CR) Rate using the IMWG response criteria
|
70 |
All |
65 Years and older (Older Adult) |
NCT03757221 |
18-070 |
IDARA |
January 1, 2019 |
December 31, 2024 |
December 31, 2025 |
November 28, 2018 |
November 28, 2018 |
|
|
|
| 17 |
NCT03180736 |
Recruiting |
Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone |
|
- Drug: Daratumumab
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- European Myeloma Network
- Janssen Research & Development, LLC
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Comparison of Progression Free Survival between treatment arms
- Overall response rate
- VGPR or better rate
- (and 12 more...)
|
302 |
All |
18 Years and older (Adult, Older Adult) |
NCT03180736 |
EMN14/54767414MMY3013 |
EMN14 |
June 12, 2017 |
June 1, 2021 |
July 1, 2023 |
June 8, 2017 |
April 13, 2018 |
|
- Antwerpen
Antwerpen, Belgium - Brussel
Brussel, Belgium - UZ Gent
Gent, Belgium - (and 38 more...)
|
|
| 18 |
NCT03695744 |
Not yet recruiting |
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma |
|
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Singapore General Hospital
- International Myeloma Foundation
- Janssen, LP
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
63 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03695744 |
AMN006 |
|
October 2018 |
March 2021 |
October 2023 |
October 4, 2018 |
October 4, 2018 |
|
- Singapore General Hospital
Singapore, Singapore
|
|
| 19 |
NCT02718833 |
Recruiting |
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma |
|
- Drug: Elotuzumab
- Drug: Pomalidomide
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Celgene
- Bristol-Myers Squibb
- Multiple Myeloma Research Consortium
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate by International Myeloma Working Group criteria.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Progression Free Survival
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT02718833 |
15-475 |
|
June 2016 |
September 2019 |
September 2023 |
March 24, 2016 |
August 7, 2018 |
|
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Mass General/North Shore Cancer Center
Danvers, Massachusetts, United States - (and 3 more...)
|
|
| 20 |
NCT02661022 |
Recruiting |
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma |
|
- Drug: SL-401/ Pomalidomide/ Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Stemline Therapeutics, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The percentage of patients with treatment-related and treatment-emergent adverse events
- SL-401 plasma concentration at multiple time points
- SL-401 maximum plasma concentration
- (and 2 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT02661022 |
STML-401-0414 |
|
January 2016 |
December 2018 |
December 2018 |
January 21, 2016 |
January 29, 2018 |
|
- City of Hope
Duarte, California, United States - Dana Farber Cancer Institue
Boston, Massachusetts, United States - Oregon Health & Science University
Portland, Oregon, United States
|
|
| 21 |
NCT03512353 |
Recruiting |
A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers |
- Relapsed or Refractory Multiple Myeloma
|
- Combination Product: Dexamethasone
- Combination Product: Carfilzomib
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of subjects completing
- Cumulative Dose
- Relative Dose Intensity
- (and 6 more...)
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03512353 |
20170596 |
|
July 5, 2018 |
January 15, 2024 |
January 15, 2024 |
April 30, 2018 |
January 17, 2019 |
|
- Research Site
Palm Springs, California, United States - Research Site
Riverside, California, United States - Research Site
Glenwood Springs, Colorado, United States - (and 27 more...)
|
|
| 22 |
NCT03785184 |
Not yet recruiting |
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy |
|
- Drug: venetoclax
- Drug: lenalidomide
- Drug: dexamethasone
|
Interventional
|
Phase 2 |
- AbbVie
- Genentech, Inc.
- Celgene Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participates Who Achieve CR
- Percent of Participants Who Achieve MRD Negativity
- Percent of Participants Who Achieve VGPR or Better
- (and 8 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03785184 |
M16-104 |
|
March 29, 2019 |
April 3, 2024 |
September 26, 2027 |
December 24, 2018 |
December 24, 2018 |
|
- University of Alabama /ID# 208307
Birmingham, Alabama, United States - Marin Cancer Care /ID# 208476
Greenbrae, California, United States - Karmanos Cancer Institute /ID# 208805
Detroit, Michigan, United States - (and 16 more...)
|
|
| 23 |
NCT03155100 |
Recruiting |
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines |
- Multiple Myeloma in Relapse
|
- Drug: Carfilzomib for Inj 60 milligram (MG)
- Drug: Elotuzumab 400 MG
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Raija Silvennoinen
- Amgen
- Bristol-Myers Squibb
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Severe adverse events
|
40 |
All |
18 Years to 74 Years (Adult, Older Adult) |
NCT03155100 |
NMSG#24/15
2016-001178-13 |
KEd |
August 7, 2017 |
June 21, 2020 |
June 30, 2023 |
May 16, 2017 |
January 8, 2019 |
|
- Helsinki University Central Hospital
Helsinki, Finland - Central Finland Central Hospital
Jyväskylä, Finland - Kymenlaakso Central Hospital
Kotka, Finland - (and 5 more...)
|
|
| 24 |
NCT03608501 |
Not yet recruiting |
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation |
|
- Drug: Ixazomib
- Drug: Thalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ORR During Induction
- Progression-free Survival (PFS)
- ORR During Maintenance
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03608501 |
C16041
U1111-1214-1078 |
IDEALL |
May 30, 2019 |
June 30, 2021 |
May 31, 2023 |
August 1, 2018 |
September 6, 2018 |
|
|
|
| 25 |
NCT01464034 |
Recruiting |
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Carfilzomib
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Criterium, Inc.
- Amgen
- Celgene Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events as a Measure of Safety and Tolerability
- Overall Response in Phase II
- Overall Response in Phase I
- (and 3 more...)
|
117 |
All |
18 Years and older (Adult, Older Adult) |
NCT01464034 |
AMyC 10-MM-01
IST-CAR-521
PO-MM-PI-0034 |
|
November 2011 |
December 2017 |
June 2018 |
November 3, 2011 |
October 18, 2017 |
|
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - The John Theurer Cancer Center @ Hackensack UMC
Hackensack, New Jersey, United States - (and 7 more...)
|
|
| 26 |
NCT03836014 |
Not yet recruiting
New |
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Combination Product: Daratumumab/Lenalidomide/Dexamethasone for 24 months
- Combination Product: Daratumumab/Lenalidomide/Dexamethasone until progression
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- Response rate
- overall response rate (ORR)
- (and 4 more...)
|
434 |
All |
18 Years and older (Adult, Older Adult) |
NCT03836014 |
D20180138
2016-002129-12 |
CONFIRM |
March 2019 |
March 2023 |
March 2025 |
February 11, 2019 |
February 11, 2019 |
|
- Saint Antoine Hospital - Hematology Department
Paris, France
|
|
| 27 |
NCT03140943 |
Recruiting |
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma |
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Carfilzomib, Thalidomide and Dexamethasone
|
Interventional
|
Phase 2 |
- National University Hospital, Singapore
- The Australasian Leukaemia & Lymphoma Group (ALLG)
- International Myeloma Foundation
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Overall Rate of Response (ORR)
- (and 4 more...)
|
100 |
All |
21 Years to 99 Years (Adult, Older Adult) |
NCT03140943 |
AMN002 |
|
September 13, 2017 |
June 1, 2019 |
June 1, 2022 |
May 4, 2017 |
November 6, 2017 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong - South Korea, Korea, Republic of
- National University Hospital
Singapore, Singapore - National Taiwan University
Taipei, Taiwan
|
|
| 28 |
NCT03590652 |
Recruiting |
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma |
- Relapsed/Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Pomalidomide
- Drug: Dexamethasone
- Drug: Daratumumab
|
Interventional
|
Phase 2 |
- Caitlin Costello, MD
- Celgene
- Takeda
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Clinical benefit rate
- (and 5 more...)
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT03590652 |
180638 |
|
October 17, 2018 |
October 1, 2020 |
October 1, 2021 |
July 18, 2018 |
January 15, 2019 |
|
- UCSD Moores Cancer Center
La Jolla, California, United States
|
|
| 29 |
NCT01665794 |
Recruiting |
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Pomalidomide
- Drug: Carfilzomib
- Drug: dexamethasone
- Drug: Daratumumab
|
Interventional
|
Phase 1
Phase 2 |
- University of Chicago
- National Cancer Institute (NCI)
- Multiple Myeloma Research Foundation
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone
- Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria
- Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab dosing according to International Myeloma Working Group (IMWG) criteria
- (and 5 more...)
|
101 |
All |
18 Years and older (Adult, Older Adult) |
NCT01665794 |
12-1088
NCI-2012-01168 |
|
August 13, 2012 |
November 2018 |
December 2018 |
August 15, 2012 |
April 3, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States - Wayne State University - Karmonos Cancer Center
Detroit, Michigan, United States - (and 2 more...)
|
|
| 30 |
NCT02253316 |
Recruiting |
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma |
|
- Biological: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
- Millennium Pharmaceuticals, Inc.
- Multiple Myeloma Research Consortium
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in minimal residual disease (MRD)
- MRD-negative rate after ASCT
- Toxicity of IRD consolidation
- (and 12 more...)
|
240 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02253316 |
201411060 |
|
January 20, 2015 |
November 30, 2019 |
August 31, 2024 |
October 1, 2014 |
January 7, 2019 |
|
- City of Hope
Duarte, California, United States - University of California, San Francisco
San Francisco, California, United States - Colorado Blood Cancer Institute
Denver, Colorado, United States - (and 7 more...)
|
|
| 31 |
NCT01090089 |
Recruiting |
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma |
|
- Drug: Lenalidomide, Dexamethasone
- Drug: Lenalidomide, Dexamethasone, PBSCT
|
Interventional
|
Phase 3 |
- Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
- ClinAssess GmbH
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall survival (OS)
- • Response (complete response [CR], stringent complete response [sCR], very good partial response [VGPR], partial response [PR] and overall response [CR (incl. sCR)+ VGPR + PR]) according to IMWG criteria
|
348 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT01090089 |
DSMM XIII |
DSM XIII |
March 1, 2010 |
December 2019 |
January 2020 |
March 19, 2010 |
September 8, 2017 |
|
- Universitätsklinikum Münster
Muenster, North Rhein Westfallen, Germany - Universitätsklinikum Aachen
Aachen, Germany - Agirov Klinik
Berg, Germany - (and 28 more...)
|
|
| 32 |
NCT03702725 |
Not yet recruiting |
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma |
- Refractory Multiple Myeloma
- Multiple Myeloma in Relapse
- Multiple Myeloma
|
- Drug: Ibrutinib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 1 |
- Alliance Foundation Trials, LLC.
- Pharmacyclics LLC.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose for Combination
- Objective Response Rate
- Progression Free Survival
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT03702725 |
AFT-15 |
|
November 1, 2018 |
May 1, 2021 |
October 1, 2021 |
October 11, 2018 |
October 11, 2018 |
|
|
|
| 33 |
NCT02004275 |
Recruiting |
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Drug: pomalidomide
- Drug: ixazomib
- Drug: dexamethasone
|
Interventional
|
Phase 1
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Celgene Corporation
- Millennium Pharmaceuticals, Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of pomalidomide and ixazomib, determined according to incidence of dose limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
- Progression free survival (PFS) (Phase II)
- Incidence and type of dose limiting toxicities (DLTs), serious adverse events, and adverse events, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
- (and 11 more...)
|
73 |
All |
18 Years and older (Adult, Older Adult) |
NCT02004275 |
A061202
NCI-2013-01702
U10CA031946 |
|
February 2014 |
March 2021 |
|
December 9, 2013 |
January 24, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 324 more...)
|
|
| 34 |
NCT01562405 |
Recruiting |
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma |
|
- Drug: ACE-011
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Pomalidomide
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Multiple Myeloma Research Consortium
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of ACE-011
- Efficacy of ACE-011
- Safety of ACE-011
- (and 2 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT01562405 |
11-318 |
|
May 2012 |
May 2018 |
August 2019 |
March 23, 2012 |
August 21, 2018 |
|
- Emory University
Atlanta, Georgia, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 35 |
NCT01572480 |
Recruiting |
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma |
|
- Drug: Carfilzomib
- Drug: Revlimid
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival
- Duration of Response
|
53 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01572480 |
120107
12-C-0107 |
|
May 29, 2012 |
June 1, 2022 |
June 1, 2023 |
April 6, 2012 |
February 15, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 36 |
NCT03234972 |
Recruiting |
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Daratumumab
- Drug: Velcade
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Time to Disease Progression (TTP)
- Overall Response Rate (ORR)
- (and 6 more...)
|
210 |
All |
18 Years and older (Adult, Older Adult) |
NCT03234972 |
CR104378
54767414MMY3009 |
|
November 30, 2017 |
September 16, 2020 |
August 31, 2022 |
August 1, 2017 |
December 13, 2018 |
|
- Beijing Chaoyang Hospital
Beijing, China - Peking Union Medical College Hospital
Beijing, China - Peking University First Hospital
Beijing, China - (and 27 more...)
|
|
| 37 |
NCT02831686 |
Recruiting |
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma |
- Multiple Myeloma
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Selinexor
- Drug: Ixazomib
- Drug: Dexamethasone
|
Interventional
|
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Karyopharm Therapeutics Inc
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose (MTD)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT02831686 |
15-310 |
|
July 2016 |
July 2019 |
July 2019 |
July 13, 2016 |
August 22, 2018 |
|
- Memoral Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States - (and 4 more...)
|
|
| 38 |
NCT02843074 |
Recruiting |
Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients |
|
- Drug: elotuzumab
- Drug: Lenalidomide
- Drug: Dexamethasone
- Procedure: autologous stem cell transplantation
|
Interventional
|
Phase 2 |
- SCRI Development Innovations, LLC
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Induction Feasibility Rate (IFR)
- Complete Response Rate (CRR)
- Overall Response Rate (ORR)
- (and 3 more...)
|
53 |
All |
18 Years and older (Adult, Older Adult) |
NCT02843074 |
SCRI MM61 |
|
September 21, 2016 |
July 2021 |
March 2022 |
July 25, 2016 |
May 24, 2018 |
|
- Colorado Blood Cancer Institute
Denver, Colorado, United States - Center for Cancer and Blood Disorders
Bethesda, Maryland, United States - HCA Midwest Health/Research Medical Center
Kansas City, Missouri, United States - (and 3 more...)
|
|
| 39 |
NCT02461888 |
Recruiting |
Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. |
|
- Drug: Ixazomib
- Drug: Cyclophosphamide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University of Leeds
- Myeloma UK
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Response to treatment
- Maximum response
- (and 8 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT02461888 |
HM13/10993 |
MUKEight |
December 2015 |
May 2018 |
May 2019 |
June 3, 2015 |
November 17, 2016 |
|
- Queen Elizabeth Medical Centre
Birmingham, United Kingdom - Heart of England NHS Foundation Trust
Birmingham, United Kingdom - Royal Bournemouth General Hospital
Bournemouth, United Kingdom - (and 15 more...)
|
|
| 40 |
NCT03652064 |
Recruiting |
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |
|
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Negative Minimal Residual Disease (MRD) Status
- Progression-Free Survival (PFS)
- MRD Negative Rate at 1 Year
- (and 14 more...)
|
360 |
All |
18 Years and older (Adult, Older Adult) |
NCT03652064 |
CR108529
2018-001545-13
54767414MMY3019 |
|
November 6, 2018 |
March 29, 2024 |
April 30, 2025 |
August 29, 2018 |
February 8, 2019 |
|
- Sharp Center for Research
San Diego, California, United States - Innovative Clinical Research, Inc.
Whittier, California, United States - Baptist MD Anderson
Jacksonville, Florida, United States - (and 122 more...)
|
|
| 41 |
NCT03433001 |
Recruiting |
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone |
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression-Free Survival (PFS)
- PFS Rate at 12 Months and 24 Months after the Start of Treatment
- Overall Survival (OS)
- (and 12 more...)
|
300 |
All |
20 Years and older (Adult, Older Adult) |
NCT03433001 |
C16042
JapicCTI-183860 |
|
April 2, 2018 |
March 31, 2021 |
March 31, 2021 |
February 14, 2018 |
July 23, 2018 |
|
- Takeda Selected Site
Tokyo, Japan
|
|
| 42 |
NCT02916420 |
Recruiting |
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma |
|
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Jiangsu Simcere Pharmaceutical Co., Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Progression-free Survival
- Duration of Response
- (and 2 more...)
|
73 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02916420 |
SIM-135-Ⅲ |
|
September 2016 |
June 2018 |
June 2019 |
September 27, 2016 |
November 2, 2016 |
|
- Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
|
|
| 43 |
NCT03539744 |
Recruiting |
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Pomalidomide
- Drug: Dexamethasone
- Drug: Venetoclax
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Very Good Partial Response or Better Response Rate (VGPR)
- Overall Response Rate (ORR)
- (and 11 more...)
|
244 |
All |
18 Years and older (Adult, Older Adult) |
NCT03539744 |
M13-494 |
CANOVA |
October 22, 2018 |
January 12, 2021 |
January 27, 2022 |
May 28, 2018 |
February 12, 2019 |
|
- VA Central California Health C /ID# 200047
Fresno, California, United States - University of California, Los Angeles /ID# 171524
Los Angeles, California, United States - Mayo Clinic /ID# 200075
Jacksonville, Florida, United States - (and 87 more...)
|
|
| 44 |
NCT03170882 |
Recruiting |
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma |
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2
Phase 3 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Percentage of Participants with Objective Response Rate (ORR - Partial Response [PR], Very Good Partial Response [VGPR] and Complete Response [CR])
- (and 9 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03170882 |
C16029
2016-004742-28
U1111-1188-2677
2017/1235
N-20170083
17/NW/0546 |
|
July 25, 2017 |
November 30, 2021 |
March 31, 2023 |
May 31, 2017 |
February 12, 2019 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - St Joseph Heritage Healthcare
Santa Rosa, California, United States - Lynn Cancer Institute
Boca Raton, Florida, United States - (and 121 more...)
|
|
| 45 |
NCT02977494 |
Recruiting |
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment |
|
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University Hospital Tuebingen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the efficacy (overall response rate, ORR according to IMWG recommendations) of the combination of daratumumab, bortezomib and dexamethasone in subjects with relapsed and refractory MM and impaired renal function
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT02977494 |
2016-000433-51 |
GMMG-DANTE |
December 2016 |
December 2020 |
December 2022 |
November 30, 2016 |
March 27, 2017 |
|
- Klinikum Augsburg
Augsburg, Germany - Charité Universitätsmedizin BerlinCampus Benjamin Franklin
Berlin, Germany - Helios Klinikum Berlin Buch
Berlin, Germany - (and 5 more...)
|
|
| 46 |
NCT02970747 |
Recruiting |
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone in Multiple Myeloma Patients |
- Multiple Myeloma in Relapse
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Patients' adherence and persistence to carfilzomib therapy
- Patients' adherence and persistence to lenalidomide and dexamethasone therapy
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02970747 |
IOM-070337 |
CARO |
October 25, 2016 |
April 2021 |
April 2022 |
November 22, 2016 |
December 20, 2018 |
|
- Centrum für Hämatologie und Onkologie Bethanien
Frankfurt, Germany
|
|
| 47 |
NCT03669445 |
Recruiting |
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma |
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Daratumumab
|
Interventional
|
Phase 2 |
- University Hospital, Toulouse
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- minimal residual disease-negativity rate
- Adverse events
- Response rates
- (and 2 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03669445 |
RC31/18/0212 |
IFM2018-01 |
December 31, 2018 |
March 2024 |
December 2024 |
September 13, 2018 |
February 4, 2019 |
|
- CHU Bordeaux
Bordeaux, France - CHU de Caen
Caen, France - CHU de Dijon
Dijon, France - (and 9 more...)
|
|
| 48 |
NCT03567616 |
Recruiting |
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Venetoclax
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
- Overall Response Rate (ORR)
- Progression-Free Survival (PFS)
- (and 8 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03567616 |
M16-085 |
|
November 9, 2018 |
August 20, 2020 |
January 22, 2021 |
June 25, 2018 |
February 8, 2019 |
|
- John B. Amos Cancer Center - C /ID# 202055
Columbus, Georgia, United States - University of Kansas Cancer Center /ID# 201292
Fairway, Kansas, United States - Dana-Farber Cancer Institute /ID# 201297
Boston, Massachusetts, United States - (and 15 more...)
|
|
| 49 |
NCT03242460 |
Recruiting |
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) |
- Relapsed and/or refractorY Multiple Myeloma
|
- Drug: Pomalidomide 4 MG
- Drug: Dexamethasone 20mg
- Drug: Cyclophosphamide 400mg
|
Interventional
|
Phase 2 |
- Kosin University Gospel Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Progression-free Survival (PFS)
- Objective Response Rate (ORR)
- Overall survival (OS)
- Safety evaluations assessed using Common Terminology Criteria for Adverse Events v4.0
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT03242460 |
PORYOU |
PORYOU |
May 12, 2015 |
December 31, 2018 |
December 31, 2019 |
August 8, 2017 |
August 8, 2017 |
|
- Catholic university of korea, Seoul ST. Mary's Hospital.
Seoul, Korea, Republic of
|
|
| 50 |
NCT02412228 |
Recruiting |
BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. |
|
- Drug: Ixazomib
- Drug: Cyclophosphamide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- John Reagan
- Rhode Island Hospital
- The Miriam Hospital
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate of Ixazomib with metronomic cyclophosphamide and dexamethasone for first-line treatment of multiple myeloma
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02412228 |
299 |
|
August 2015 |
May 2019 |
September 2019 |
April 9, 2015 |
November 30, 2018 |
|
- Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, United States - Rhode Island Hospital
Providence, Rhode Island, United States - The Miriam Hospital
Providence, Rhode Island, United States
|
|
| 51 |
NCT03173092 |
Recruiting |
An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) |
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 4 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Percentage of Participants with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR)
- Duration of Response
- (and 3 more...)
|
160 |
All |
18 Years and older (Adult, Older Adult) |
NCT03173092 |
C16038
U1111-1192-7696 |
|
September 20, 2017 |
November 30, 2023 |
November 30, 2023 |
June 1, 2017 |
February 6, 2019 |
|
- Arizona Oncology Associates, P.C.
Tucson, Arizona, United States - CARTI Cancer Center
Little Rock, Arkansas, United States - Pacific Cancer Medical Center
Anaheim, California, United States - (and 25 more...)
|
|
| 52 |
NCT03544281 |
Recruiting |
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
- Drug: GSK2857916
- Drug: Lenalidomide
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with AE's and serious adverse events (SAEs),Part 1
- Number of subjects with electrocardiogram (ECG) parameters of potential clinical importance (PCI), Part 1
- Number of subjects with abnormal hematology parameters, Part 1
- (and 69 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03544281 |
207497 |
|
September 20, 2018 |
June 29, 2020 |
November 28, 2022 |
June 1, 2018 |
October 12, 2018 |
|
- GSK Investigational Site
Birmingham, Alabama, United States
|
|
| 53 |
NCT02659293 |
Recruiting |
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Carfilzomib
- Drug: Dexamethasone
- Drug: Lenalidomide (Control)
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival rates in participants receiving drug combination
- Rate of minimal residual negative disease (MRD) in participants receiving drug combination
- Response rate in participants receiving drug combination
- Treatment-related side effects
|
180 |
All |
18 Years and older (Adult, Older Adult) |
NCT02659293 |
IRB15-1286 |
|
April 26, 2016 |
March 2019 |
May 2020 |
January 20, 2016 |
March 13, 2018 |
|
- University of Chicago
Chicago, Illinois, United States - Wayne State University - Karmanos Cacner Institute
Detroit, Michigan, United States - Polish Myeloma Consortium
Poznań, Poland
|
|
| 54 |
NCT03729804 |
Not yet recruiting |
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) |
|
- Drug: Carfilzomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Bortezomib
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with progression free survival with the group taking KRd versus VRd after randomization
- The rate of MRD-negative (minimal residual disease) at indicated time points of study after randomization
- The combination of drugs (KRd vs VRd) with the best response using minimal residual disease analysis across entire treatment in high risk and low risk patients
- (and 2 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT03729804 |
IRB18-1243 |
(COBRA) |
December 24, 2018 |
December 24, 2021 |
December 24, 2023 |
November 5, 2018 |
November 5, 2018 |
|
- University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
|
|
| 55 |
NCT02916771 |
Recruiting |
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma |
- Smoldering Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Celgene
- Takeda
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy
- Progression Free Survival
- Time To Progression
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02916771 |
16-313 |
|
October 2016 |
April 2020 |
April 2024 |
September 27, 2016 |
January 7, 2019 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 56 |
NCT03314181 |
Recruiting |
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Dexamethasone
- Drug: Daratumumab
- Drug: Venetoclax
- Drug: Bortezomib
|
Interventional
|
Phase 2 |
- AbbVie
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part 1: Objective Response Rate (ORR)
- Part 1: Number of Participants with Dose Limiting Toxicities (DLT)
- Part 2: Number of Participants with Dose Limiting Toxicities (DLT)
- (and 12 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03314181 |
M15-654
2017-002099-26 |
|
March 12, 2018 |
November 4, 2020 |
March 22, 2023 |
October 19, 2017 |
February 11, 2019 |
|
- Univ of Colorado Cancer Center /ID# 167331
Aurora, Colorado, United States - H. Lee Moffitt Cancer Center /ID# 169614
Tampa, Florida, United States - Emory University Hospital /ID# 165427
Atlanta, Georgia, United States - (and 28 more...)
|
|
| 57 |
NCT02773030 |
Recruiting |
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) |
|
- Drug: CC-220
- Drug: Dexamethasone
- Drug: Daratumumab
- Drug: Bortezomib (BTZ)
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Dose Limiting Toxicity (DLT)
- Establish Recommended Phase 2 doses (RP2Ds)
- (and 12 more...)
|
154 |
All |
18 Years and older (Adult, Older Adult) |
NCT02773030 |
CC-220-MM-001 |
|
October 14, 2016 |
March 16, 2021 |
January 14, 2023 |
May 16, 2016 |
January 18, 2019 |
|
- Mayo Clinic
Scottsdale, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Winship Cancer Institute of Emory University
Atlanta, Georgia, United States - (and 31 more...)
|
|
| 58 |
NCT02542657 |
Recruiting |
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma |
|
- Drug: Clarithromycin
- Drug: Dexamethasone
- Drug: Ixazomib Citrate
- Drug: Pomalidomide
|
Interventional
|
Phase 1
Phase 2 |
- University of California, Davis
- Takeda
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
- Clinical best response
|
52 |
All |
18 Years and older (Adult, Older Adult) |
NCT02542657 |
728937
UCDCC#253
X16043
PO-TR-MM-PI-004614 |
|
October 2015 |
May 2020 |
July 2020 |
September 7, 2015 |
March 2, 2018 |
|
- University of California San Diego
La Jolla, California, United States - University of California Irvine
Orange, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
|
|
| 59 |
NCT03030261 |
Recruiting |
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Drug: Elotuzumab
- Drug: Pomalidomide
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
- Bristol-Myers Squibb
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS) rate
- Overall response rate (ORR)
- Complete response rate (CRR)
- (and 5 more...)
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03030261 |
201701084
CA204-225
PO-CL-MM-PI-008341 |
|
November 22, 2017 |
May 31, 2021 |
February 28, 2026 |
January 24, 2017 |
January 21, 2019 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 60 |
NCT03809780 |
Not yet recruiting |
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Kosin University Gospel Hospital
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
102 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT03809780 |
LENDER |
LENDER |
February 1, 2019 |
December 1, 2023 |
December 3, 2024 |
January 18, 2019 |
January 18, 2019 |
|
- Kosin University Gospel Hospital
Busan, Western, Korea, Republic of
|
|
| 61 |
NCT02586038 |
Recruiting |
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS |
|
- Drug: MLN9708
- Drug: Dexamethasone
- Drug: Cyclophosphamide
- Drug: Thalidomide
|
Interventional
|
Phase 2 |
- Silvio Aime
- University of Turin, Italy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Response rate
- Toxicity in terms of rate of hematologic and non-hematologic adverse events
- (and 4 more...)
|
183 |
All |
65 Years and older (Older Adult) |
NCT02586038 |
UNITO-EMN10 |
|
October 2015 |
October 2020 |
October 2023 |
October 26, 2015 |
February 19, 2018 |
|
- AO SS Antonio e Biagio e Cesare Arrigo di Alessandria
Alessandria, Italy
|
|
| 62 |
NCT03375567 |
Recruiting |
Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone |
|
- Procedure: Guided Lesion Biopsies
- Procedure: Standard Lesion Biopsies
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Detection rate of residual/refractory
- Myeloma lesion response rate
- Overall clinical response rate
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03375567 |
2000021421 |
|
June 4, 2018 |
March 2020 |
September 2020 |
December 18, 2017 |
July 27, 2018 |
|
- Yale Cancer Center
New Haven, Connecticut, United States
|
|
| 63 |
NCT02939183 |
Recruiting |
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma |
- Relapsed or Refractory Multiple Myeloma
|
- Drug: Immediate Release (IR) Formulation
- Drug: Gastro-Retentive (GR) Formulation
- Drug: Dexamethasone
- Drug: Pomalidomide
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone
|
64 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT02939183 |
20160104 |
INTREPID-1 |
January 17, 2017 |
April 29, 2020 |
April 29, 2020 |
October 19, 2016 |
February 8, 2019 |
|
- Research Site
West Hollywood, California, United States - Research Site
Tampa, Florida, United States - Research Site
Atlanta, Georgia, United States - (and 15 more...)
|
|
| 64 |
NCT02969837 |
Recruiting |
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma |
|
- Drug: Elotuzumab
- Drug: Carfilzomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University of Chicago
- Bristol-Myers Squibb
- Amgen
- Multiple Myeloma Research Foundation
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of sCR
- Rate of negative MRD
- Number of participants with adverse events of elotuzumab in combination with KRd
- (and 5 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT02969837 |
IRB16-1138 |
|
July 10, 2017 |
December 2019 |
December 2020 |
November 21, 2016 |
February 21, 2018 |
|
- University of Chicago
Chicago, Illinois, United States - NorthShore University Health System
Evanston, Illinois, United States - University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
|
|
| 65 |
NCT03798678 |
Recruiting |
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Carfilzomib
- Drug: Dexamethasone
- Drug: Glutaminase Inhibitor CB-839 Hydrochloride
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) and recommended phase II dose (RP2D)
- Incidence of adverse events
- Overall response rate (ORR)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03798678 |
NCI-2019-00111
10219
UM1CA186686 |
|
December 26, 2018 |
January 30, 2022 |
January 30, 2022 |
January 10, 2019 |
January 10, 2019 |
|
- Mayo Clinic Cancer Center LAO
Rochester, Minnesota, United States
|
|
| 66 |
NCT03710603 |
Recruiting |
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma |
|
- Drug: Daratumumab
- Drug: velcade
- Drug: Lenalidomide
- Drug: dexamethasone
|
Interventional
|
Phase 3 |
- European Myeloma Network
- Janssen Research & Development, LLC
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Post-consolidation MRD negativity rate,
- Overall Response Rate (ORR)
- (and 11 more...)
|
690 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03710603 |
EMN17/54767414MMY3014 |
Perseus |
December 14, 2018 |
May 2029 |
November 2029 |
October 18, 2018 |
January 17, 2019 |
|
- Alfred Hospital
Melbourne, Australia - University Hospital Leuven
Leuven, Belgium - University Hospital Ostrava
Ostrava, Czechia - (and 10 more...)
|
|
| 67 |
NCT03136653 |
Recruiting |
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma |
- Multiple Myeloma in Relapse
|
- Biological: MP0250 plus BOR+DEX
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimate the efficacy of MP0250 plus BOR + DEX based on overall response rate (ORR)
- Determine the safety profile of MP0250 plus BOR + DEX
- Determine the immunogenicity of MP0250 plus BOR + DEX
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03136653 |
MP0250-CP201
2016-002771-10 |
|
May 23, 2017 |
October 2019 |
December 2019 |
May 2, 2017 |
February 18, 2019 |
|
- University of Essen, Haematology
Essen, Germany - University of Heidelberg, Haematology, Oncology
Heidelberg, Germany - University of Würzburg, Haematology, Oncology
Würzburg, Germany - (and 6 more...)
|
|
| 68 |
NCT02278315 |
Recruiting |
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: I-131-CLR1404
- Drug: dexamethasone
|
Interventional
|
Phase 1 |
- Cellectar Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with dose limiting toxicities (DLT)
- Identification of recommended phase 2 dose of I-131-CLR1404 with concurrent weekly dexamethasone
- Identification of recommended phase 2 dose of I-131-CLR1404 without dexamethasone
- Identify the recommended dosing schedule of I-131-CLR1404, in relapsed or refractory MM
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT02278315 |
DCL-14-002 |
|
February 2015 |
June 2019 |
September 2019 |
October 30, 2014 |
January 8, 2019 |
|
- Mayo Clinic
Jacksonville, Florida, United States - Loyola University Medical Center
Maywood, Illinois, United States - Karmanos Cancer Institute
Detroit, Michigan, United States - University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
|
| 69 |
NCT02952573 |
Recruiting |
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement |
- Multiple Myeloma
- Relapsed/Refractory
|
- Drug: JNJ-42756493
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
- Multiple Myeloma Research Consortium
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- Minimal response rate
- Stable disease rate
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02952573 |
PM-MM003 |
|
June 13, 2017 |
January 2023 |
December 2023 |
November 2, 2016 |
February 4, 2019 |
|
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
|
| 70 |
NCT03150316 |
Recruiting |
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma |
|
|
Interventional
|
Phase 1 |
- Chong Kun Dang Pharmaceutical
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD
- Pharmacokinetics(Cmax)
|
18 |
All |
19 Years and older (Adult, Older Adult) |
NCT03150316 |
133MM16016 |
|
May 10, 2017 |
June 29, 2018 |
November 19, 2019 |
May 12, 2017 |
June 9, 2017 |
|
- Samsung Hospital
Soul, Gangnam-gu, Korea, Republic of - the catholic university of korea, Seoul ST. Mary's Hospital
Seoul, Seocho, Korea, Republic of
|
|
| 71 |
NCT03457142 |
Recruiting |
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Biological: Abatacept
- Drug: Dexamethasone
- Drug: Ixazomib Citrate
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate of abatacept + ixazomib citrate + dexamethasone in multiple myeloma patients
- Incidence of adverse events assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Overall survival
- Progression-free survival
|
19 |
All |
18 Years and older (Adult, Older Adult) |
NCT03457142 |
I 47217
NCI-2017-02430
P30CA016056 |
|
June 25, 2018 |
November 8, 2019 |
November 8, 2020 |
March 7, 2018 |
November 29, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 72 |
NCT03376672 |
Recruiting |
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients |
|
- Drug: Ixazomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- Raija Silvennoinen
- Nordic Myeloma Study Group
- Celgene
- (and 2 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Flow cytometric assessment < 0.01%
- Flow cytometry negativity
|
120 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03376672 |
NMSG#23/15 |
|
May 31, 2018 |
December 31, 2027 |
December 31, 2027 |
December 18, 2017 |
January 8, 2019 |
|
- Helsinki University Central Hospital
Helsinki, Finland - Central Finland Central Hospital
Jyväskylä, Finland - Kainuu Central Hospital
Kajaani, Finland - (and 23 more...)
|
|
| 73 |
NCT03713294 |
Recruiting |
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma |
- Refractory Plasma Cell Myeloma
|
- Drug: Dexamethasone
- Biological: Elotuzumab
- Drug: Pomalidomide
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as a partial response, very good partial response, complete response (CR) or stringent CR (sCR)
- Percentage of patients achieving complete response (CR)
- Progression-free survival (PFS)
- (and 2 more...)
|
41 |
All |
18 Years and older (Adult, Older Adult) |
NCT03713294 |
MC1884
NCI-2018-02140
P30CA015083 |
|
December 19, 2018 |
October 8, 2023 |
October 8, 2023 |
October 19, 2018 |
January 3, 2019 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States
|
|
| 74 |
NCT03617731 |
Recruiting |
Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) |
|
- Drug: Lenalidomide
- Drug: Bortezomib
- Drug: Dexamethasone
- Drug: Isatuximab
|
Interventional
|
Phase 3 |
- University of Heidelberg Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MRD negativity after induction Treatment (comparison of arms IA and IB)
- Progression Free Survival (PFS) after second randomization (arms IIA and IIB)
- to compare the four treatment arms (IA-IIA, IA-IIB, IB-IIA, IB-IIB) regarding Progression free survival (PFS)
- (and 13 more...)
|
662 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03617731 |
GMMG HD7 |
|
October 18, 2018 |
May 2025 |
December 2025 |
August 6, 2018 |
October 29, 2018 |
|
- HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie
Berlin, Germany - Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin
Bielefeld, Germany - Medizinische Universitätsklinik, Knappschaftskrankenhaus
Bochum, Germany - (and 28 more...)
|
|
| 75 |
NCT03756896 |
Recruiting |
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma |
|
- Drug: Carfilzomib
- Drug: Dexamethasone
- Drug: Pomalidomide
|
Interventional
|
Phase 2 |
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ≥ Complete response (CR) rates
- Progression-free survival (PFS)
- Best response on-study
- (and 4 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT03756896 |
IRB00097882
NCI-2017-02052
Winship4101-17 |
|
January 25, 2019 |
January 30, 2021 |
November 30, 2021 |
November 28, 2018 |
February 12, 2019 |
|
- Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
|
|
| 76 |
NCT03275285 |
Recruiting |
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients |
|
- Drug: isatuximab SAR650984
- Drug: carfilzomib
- Drug: dexamethasone
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Response Rate (ORR)
- Rate of VGPR or better
- (and 11 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03275285 |
EFC15246
2017-001940-37
U1111-1195-5957 |
IKEMA |
October 25, 2017 |
November 2023 |
November 2023 |
September 7, 2017 |
February 20, 2019 |
|
- Investigational Site Number 8400002
San Francisco, California, United States - Investigational Site Number 8400003
Spartanburg, South Carolina, United States - Investigational Site Number 0360005
Blacktown, Australia - (and 67 more...)
|
|
| 77 |
NCT02654990 |
Recruiting |
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma |
|
- Drug: panobinostat capsules
- Drug: bortezomib injection
- Drug: dexamethasone tablets
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) up to 8 cycles
- ORR throughout study
- individual immunophenotypic complete response (CR) rate
- (and 14 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT02654990 |
CLBH589D2222 |
PANORAMA_3 |
April 27, 2016 |
June 10, 2019 |
December 15, 2022 |
January 13, 2016 |
February 20, 2019 |
|
- Highlands Oncology Group
Fayetteville, Arkansas, United States - Los Angeles Hematology/Oncology Medical Group Wilson Terr
Los Angeles, California, United States - Poudre Valley Hospital SC
Fort Collins, Colorado, United States - (and 90 more...)
|
|
| 78 |
NCT03701321 |
Recruiting |
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Bortezomib
- Biological: Daratumumab
- Drug: Dexamethasone
- Drug: Venetoclax
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of venetoclax in combination with daratumumab, bortezomib and dexamethasone (Phase I)
- Minimal residual disease (MRD) negative status (Phase II)
- Overall survival (OS) (Phase II)
- (and 4 more...)
|
282 |
All |
18 Years and older (Adult, Older Adult) |
NCT03701321 |
NCI-2018-02131
EAA172
U10CA180820 |
|
January 25, 2019 |
October 31, 2023 |
October 31, 2023 |
October 10, 2018 |
February 11, 2019 |
|
- Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, United States
|
|
| 79 |
NCT03051841 |
Recruiting |
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma |
|
|
Interventional
|
Phase 1 |
- Chong Kun Dang Pharmaceutical
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose(MTD)
- Pharmacokinetics(Cmax)
- Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year
- (and 10 more...)
|
18 |
All |
19 Years and older (Adult, Older Adult) |
NCT03051841 |
133MM16010 |
|
January 2017 |
June 2019 |
June 2021 |
February 14, 2017 |
July 26, 2018 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
|
| 80 |
NCT03413800 |
Recruiting |
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant |
- Relapsed Hematologic Malignancy
- Multiple Myeloma
|
- Drug: Lenalidomide-Dexamethasone-DLI
|
Interventional
|
Phase 2 |
- Ciusss de L'Est de l'Île de Montréal
- Celgene
- Centre de Commercialisation en Immunothérapie du Cancer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of Len-Dex-DLI in patients with relapsed myeloma measured by progression-free survival
- Incidence of grade ≥III non hematologic toxicity and incidence of grade ≥IV hematologic toxicity
- Incidence of acute GVHD
- (and 10 more...)
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03413800 |
HMR003 |
|
February 12, 2018 |
January 29, 2021 |
January 29, 2023 |
January 29, 2018 |
January 31, 2019 |
|
- CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond
Montréal, Quebec, Canada
|
|
| 81 |
NCT03500445 |
Not yet recruiting |
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma |
|
- Drug: Daratumumab
- Drug: Carfilzomib
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
- University of Chicago
- Janssen Scientific Affairs, LLC
- Amgen
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of stringent complete response (sCR)
- Rate of minimal residual disease (MRD)-negative disease as assessed by Next Generation Sequencing
- Long term rate of MRD-negative disease
- (and 6 more...)
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03500445 |
IRB17-1097 |
|
January 2019 |
June 2021 |
January 2023 |
April 17, 2018 |
December 11, 2018 |
|
- The University of Chicago
Chicago, Illinois, United States
|
|
| 82 |
NCT03202628 |
Recruiting |
Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Dexamethasone
- Drug: Ixazomib Citrate
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival at 18 months (PFS18) defined as the proportion of patients alive and free from disease progression at 18 months from study entry
- Greater than or equal to (>=) very good partial response (VGPR) rate
- Incidence of adverse events graded according to the National Cancer Institute (NC) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4
- (and 2 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT03202628 |
MC168A
NCI-2017-01145
P30CA015083 |
|
July 24, 2017 |
July 24, 2022 |
July 24, 2022 |
June 28, 2017 |
August 14, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 83 |
NCT03104270 |
Recruiting |
Combination Study for High Risk Multiple Myeloma Patients |
|
- Drug: Elotuzumab
- Drug: Pomalidomide
- Drug: Carfilzomib
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
- Efficacy
- PFS
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03104270 |
CA204-187 |
|
March 13, 2017 |
February 2020 |
May 2020 |
April 7, 2017 |
January 8, 2019 |
|
- California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States - Robert A. Moss, MD, FACP, Inc
Fountain Valley, California, United States - Pacific Cancer Care
Monterey, California, United States - (and 3 more...)
|
|
| 84 |
NCT03256045 |
Recruiting |
Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Carfilzomib
- Other: Chemosensitivity Assay
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Partial response (PR) rate
- Very good partial response (VGPR) rate
- Complete Response (CR) rate
- (and 7 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03256045 |
9757
NCI-2017-00453
P30CA015704 |
|
February 8, 2018 |
May 16, 2021 |
May 16, 2024 |
August 21, 2017 |
November 12, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 85 |
NCT02315716 |
Recruiting |
Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma |
|
- Procedure: Autologous Stem Cell Transplant (ASCT)
- Drug: Consolidation with 4 cycles of CarCyDex
|
Interventional
|
Phase 2 |
- University College, London
- Amgen (Europe) GmbH
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- PFS
- Toxicity
- (and 4 more...)
|
280 |
All |
18 Years and older (Adult, Older Adult) |
NCT02315716 |
UCL/12/0500 |
Cardamon |
May 2015 |
November 2018 |
November 2026 |
December 12, 2014 |
February 28, 2018 |
|
- Queen's Hospital
Romford, Essex, United Kingdom - Royal United Hospital
Bath, United Kingdom - Queen Elizabeth Hospital
Birmingham, United Kingdom - (and 15 more...)
|
|
| 86 |
NCT03416374 |
Recruiting |
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy |
- Relapsed and/or Refractory Multiple Myeloma
|
- Drug: Ixazomib
- Drug: Bortezomib
- Drug: Carfilzomib
- (and 2 more...)
|
Interventional
|
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) Rate at 12 Months from the Start of Study Treatment
- Overall Survival (OS) from the Start of Study Treatment
- PFS from the Start of Study Treatment
- (and 13 more...)
|
47 |
All |
20 Years and older (Adult, Older Adult) |
NCT03416374 |
C16043
U1111-1207-0061
JapicCTI-183839 |
|
March 13, 2018 |
February 28, 2020 |
May 31, 2021 |
January 31, 2018 |
July 23, 2018 |
|
- Kameda Medical Center
Kamogawa, Chiba, Japan - The Jikei University Kashiwa Hospital
Kashiwa, Chiba, Japan - Ogaki Municipal Hospital
Ogaki, Gifu, Japan - (and 20 more...)
|
|
| 87 |
NCT03589222 |
Recruiting |
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma |
- Refractory Multiple Myeloma
|
- Drug: Selinexor
- Drug: Daratumumab
- Drug: Bortezomib
- Drug: Dexamethasone
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of responses type to treatment
- Incidence of Treatment-Emergent Adverse Events
|
62 |
All |
18 Years and older (Adult, Older Adult) |
NCT03589222 |
GEM- SELIBORDARA |
|
July 15, 2018 |
June 2019 |
June 2022 |
July 17, 2018 |
July 27, 2018 |
|
- Hospital Germans Trials i Pujol
Badalona, Spain - Hospital Clinic de Barcelona
Barcelona, Spain - Hospital ICO de Girona
Girona, Spain - (and 12 more...)
|
|
| 88 |
NCT03731832 |
Recruiting |
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide: A Study in Relapsed or Refractory Multiple Myeloma |
- Refractory Multiple Myeloma
|
- Drug: MLN9708
- Drug: Pomalidomide 4 MG Oral Capsule
- Drug: Dexamethasone
- Drug: Cyclophosphamide
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Overall Response rate (PId) according to the IMWG criteria.
- Disease control rate
- Overall response rate
- (and 4 more...)
|
82 |
All |
18 Years and older (Adult, Older Adult) |
NCT03731832 |
DSMM XV |
|
September 20, 2018 |
February 2021 |
February 2022 |
November 6, 2018 |
January 3, 2019 |
|
- Klinikum rechts der Isar der TU München / III. Med. Klinik und Poliklinik
Munich, Bayern, Germany - phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg
Aschaffenburg, Germany - Sozialstiftung Bamberg / Klinik am Bruderwald, Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie
Bamberg, Germany - (and 8 more...)
|
|
| 89 |
NCT03763162 |
Not yet recruiting |
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
|
- Drug: Bortezomib
- Biological: Daratumumab
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Takeda
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) assessed by International Myeloma Working Group Criteria (IMWG)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03763162 |
2018-0512
NCI-2018-02830
P30CA016672 |
|
April 30, 2019 |
December 31, 2023 |
December 31, 2023 |
December 4, 2018 |
February 19, 2019 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 90 |
NCT02516696 |
Recruiting |
BiRd vs. Rd as Initial Therapy in Multiple Myeloma |
|
- Drug: Clarithromycin
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Weill Medical College of Cornell University
- Celgene Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival duration without disease progression
- Number of subjects who demonstrate a response to BiRd treatment regimen
- Number of adverse events experienced
- (and 2 more...)
|
320 |
All |
65 Years and older (Older Adult) |
NCT02516696 |
1411015662
RV-CL-MM-PI-004078 |
BiRd vs Rd |
February 2016 |
August 2020 |
August 2021 |
August 6, 2015 |
October 22, 2018 |
|
- Weill Cornell Medical College
New York, New York, United States
|
|
| 91 |
NCT02406222 |
Recruiting |
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) |
|
- Drug: Pomalidomide
- Drug: Dexamethasone
- Drug: Cyclophosphamide
|
Interventional
|
Phase 2 |
- University of Leeds
- Myeloma UK
- Celgene
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Maximum response overall
- Response to treatment
- (and 6 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT02406222 |
HM13/10758 |
MUKseven |
March 2016 |
March 2019 |
March 2023 |
April 2, 2015 |
June 16, 2017 |
|
- Belfast Health & Social Care Trust
Belfast, United Kingdom - University of Birmingham NHS Foundation Trust
Birmingham, United Kingdom - Birmingham Heartlands Hospital
Birmingham, United Kingdom - (and 18 more...)
|
|
| 92 |
NCT03290950 |
Recruiting |
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: daratumumab
- Drug: carfilzomib
- Drug: lenalidomide
- Drug: dexamethasone
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Janssen Pharmaceuticals
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- assess the rate of MRD negativity
|
41 |
All |
18 Years and older (Adult, Older Adult) |
NCT03290950 |
17-352 |
|
September 25, 2017 |
September 2020 |
September 2020 |
September 25, 2017 |
January 23, 2019 |
|
- Memoral Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States - (and 4 more...)
|
|
| 93 |
NCT02633059 |
Recruiting |
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
- Loss of Chromosome 17p
- Recurrent Plasma Cell Myeloma
|
- Drug: Dexamethasone
- Drug: Idasanutlin
- Drug: Ixazomib Citrate
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events profile graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Incidence of toxicity graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Maximum tolerated dose (MTD) of ixazomib citrate and idasanutlin in combination with dexamethasone (Phase I)
- (and 6 more...)
|
53 |
All |
18 Years and older (Adult, Older Adult) |
NCT02633059 |
MC1582
NCI-2015-02155
NP29909
X16066
MMRC-061
P30CA015083 |
|
December 30, 2015 |
May 13, 2021 |
May 13, 2021 |
December 17, 2015 |
July 12, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States - (and 5 more...)
|
|
| 94 |
NCT03605056 |
Not yet recruiting |
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM |
|
- Drug: chidamide
- Drug: lenalidomide
- Drug: dexamethasone
|
Interventional
|
Phase 2 |
- Peng Liu
- Chipscreen Biosciences, Ltd.
- Shanghai Zhongshan Hospital
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Number of participants with treatment-related adverse events
- Overall Survival Rate
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT03605056 |
SHZS-MM001 |
|
July 31, 2018 |
July 31, 2020 |
July 31, 2022 |
July 30, 2018 |
July 30, 2018 |
|
- 180 Fenglin Road
Shanghai, Shanghai, China
|
|
| 95 |
NCT03151811 |
Recruiting |
A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide |
|
- Drug: Melflufen
- Drug: Pomalidomide
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Response Rate (ORR)
- Duration of Response (DOR)
- (and 2 more...)
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT03151811 |
OP-103 |
OCEAN |
June 13, 2017 |
December 2019 |
December 2021 |
May 12, 2017 |
February 15, 2019 |
|
- US17
Tucson, Arizona, United States - US03
Berkeley, California, United States - US01
Fresno, California, United States - (and 111 more...)
|
|
| 96 |
NCT03556332 |
Recruiting |
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation |
|
- Drug: Carfilzomib
- Drug: Lenalidomide
- Drug: Dexamethasone
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Janssen Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients with complete remission (CR) rate
|
46 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03556332 |
17-493 |
|
July 2, 2018 |
June 2021 |
June 2021 |
June 14, 2018 |
February 7, 2019 |
|
- Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memoral Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States - (and 4 more...)
|
|
| 97 |
NCT03215524 |
Recruiting |
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide |
|
- Biological: DCdP
- Biological: DCd+P
|
Interventional
|
Phase 2 |
- Myeloma Canada Research Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03215524 |
MCRN 004 |
DCDP |
October 25, 2017 |
October 2020 |
March 2023 |
July 12, 2017 |
June 12, 2018 |
|
- Tom Baker Cancer Centre
Calgary, Alberta, Canada - CrossCancer Institute
Edmonton, Alberta, Canada - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada - (and 8 more...)
|
|
| 98 |
NCT03601624 |
Recruiting |
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans |
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Refractory Multiple Myeloma
|
|
Interventional
|
Phase 2 |
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: Incidence of Treatment - Emergent Adverse Events
- Efficacy as secondary endpoints: progression free survival, overall survival and overall response rate
|
18 |
All |
18 Years and older (Adult, Older Adult) |
NCT03601624 |
ISSSTE-POM-CY-MM-2018 |
MM-POM-2018 |
September 1, 2018 |
December 31, 2018 |
July 30, 2020 |
July 26, 2018 |
November 14, 2018 |
|
- ISSSTE
Ciudad de Mexico, Mexico
|
|
| 99 |
NCT03143036 |
Recruiting |
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma |
- Relapse and / or Refractory Myeloma
|
- Drug: Daratumumab, thalidomide and dexamethasone
|
Interventional
|
Phase 2 |
- National University Hospital, Singapore
- Janssen, LP
- International Myeloma Foundation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall Response Rate (ORR)
- Overall survival (OS)
- (and 2 more...)
|
100 |
All |
21 Years to 99 Years (Adult, Older Adult) |
NCT03143036 |
AMN004 |
|
May 1, 2018 |
July 1, 2019 |
July 1, 2022 |
May 8, 2017 |
June 7, 2018 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong - Samsung Medical Center
South Korea, Korea, Republic of - National University Hospital
Singapore, Singapore - (and 2 more...)
|
|
| 100 |
NCT01863550 |
Recruiting |
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Bortezomib
- Drug: Carfilzomib
- Drug: Dexamethasone
- (and 3 more...)
|
Interventional
|
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) for the maintenance analysis
- Progression-free survival for the induction analysis
- Progression-free survival for the maintenance analysis
- (and 16 more...)
|
1080 |
All |
18 Years and older (Adult, Older Adult) |
NCT01863550 |
E1A11
NCI-2012-02608
ECOG-E1A11
s17-00040
U10CA180820
U10CA021115
U24CA196172 |
|
December 2, 2013 |
November 1, 2023 |
|
May 29, 2013 |
August 22, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 917 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: